Gastrointestinal Cancer

Panel 01 - (INTERACTIVE) HyTEC Report: SBRT/SABR in Abdominal Regions

1:15 PM - 2:45 PM
Location: Room 301

Session Type: Panel
1.50 AMA PRA Category 1 Credits™
1.50 CAMPEP Credits
1.50 MDCB Credits

Adrenal, pancreas and liver tumors have been successfully treated with stereotactic body radiation therapy (SBRT)/stereotactic ablative body radiotherapy (SABR), and a sufficient amount of data has been published to begin quantitative analyses of tumor control and dose tolerance. Dose-response models are the foundation of dose tolerance guidelines in the Rubin and Casarett textbook (1), the Emami paper (2), and in QUANTEC (3), and the goal of the High Dose per Fraction/Hypofractionated Treatment Effects in the Clinic (HyTEC) project is to apply this methodology to SBRT. HyTEC is organized by disease site to review and analyze the relevant SBRT literature. In this session, we will be presenting models that were derived from the published data to predict the dose response relationship between hypofractionated SBRT doses and tumor control probability for adrenal, pancreas and liver tumors, as well as normal tissue complication rates of liver and the gastrointestinal tract after abdominal SBRT.

Learning Objectives:


Jimm Grimm, PhD

Johns Hopkins University: Employee: Employee

DiversiLabs, LLC: Patent/License Fees/Copyright

AAPM SBRT Working Group: Co-Chair


Send Email for Jimm Grimm

Ellen Yorke, PhD, FASTRO

Memorial Sloan Kettering Cancer Center: Attending Physicist: Employee

AAPM: Co-chair of WGSBRT, member at large of Board of Directors


Send Email for Ellen Yorke


Panel 01 - (INTERACTIVE) HyTEC Report: SBRT/SABR in Abdominal Regions

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Panel 01 - (INTERACTIVE) HyTEC Report: SBRT/SABR in Abdominal Regions